A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

NCT01709903 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

744

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: QVA149
DRUG: Fluticasone/salmeterol
DRUG: Placebo to QVA149
DRUG: Placebo to fluticasone/salmeterol

Sponsor

Novartis Pharmaceuticals